Tempus AI has agreed to acquire Personalis in a $1.5bn stock deal positioned to strengthen the company’s oncology provision with minimal residual disease (MRD) testing. […]
While Bitcoin and Ethereum lost nearly 40% over the past 12 months, AXT Inc. surged more than 5,100%, becoming one of the most impressive AI-linked […]